Liang Zhu

age ~48

from Ontario, CA

Get Report

Also known as:

Liang Z Hu
Zhu Liong

Connected to:

Liang Zhu Phones & Addresses

Ontario, CA
Missouri City, TX
Richmond, TX
Great Neck, NY
Jersey City, NJ
Houston, TX
Vernon Hills, IL
Palisades Park, NJ
Chicago, IL

Us Patents

Multi-Microrna Methods And Compositions
view source
US Patent:

8114982, Feb 14, 2012
Filed:

Nov 28, 2007
Appl. No.:

12/312616
Inventors:

Liang Zhu - Ardsley NY, US
Daqian Sun - Bronx NY, US
Assignee:

Albert Einstein College of Medicine of Yeshiva University - Bronx NY
International Classification:

C07H 21/04
US Classification:

536 245, 536 2431, 536 241, 514 44
Abstract:

Provided are DNAs comprising a polynucleotide that encodes at least a first modified miR- precursor and a second modified miR- precursor. Also provided are vectors comprising the the DNAs, where the vector can replicate in a host cell. Additionally, specific lentiviral vectors comprising the above-described DNA are provided, as are methods of inhibiting expression of a target gene in a eukaryotic cell.

Inhibition Of Skp2-Cyclin A Interaction
view source
US Patent:

8173604, May 8, 2012
Filed:

May 23, 2007
Appl. No.:

12/226935
Inventors:

Liang Zhu - Ardsley NY, US
Peng Ji - Watertown MA, US
Assignee:

Albert Einstein College of Medicine of Yeshiva University - Bronx NY
International Classification:

A61K 38/10
A61K 38/16
US Classification:

514 214
Abstract:

Methods of killing a cancer cell are provided. Also provided are methods of treating a subject having a cancer. Additionally, compounds are provided that comprise a peptide from about 18 to about 100 amino acids or peptidomimetics comprising the sequence of SEQ ID NO:1. Additionally provided are methods of screening an agent for the ability to kill a cancer cell.

Compounds That Are Erk Inhibitors
view source
US Patent:

8546404, Oct 1, 2013
Filed:

Jun 5, 2007
Appl. No.:

11/810282
Inventors:

Alan B. Cooper - West Caldwell NJ, US
Yongqi Deng - Newton MA, US
Neng-Yang Shih - Lexington MA, US
Hugh Y. Zhu - Scotch Plains NJ, US
Robert Sun - Natick MA, US
Joseph M. Kelly - Parlin NJ, US
Ronald J. Doll - Convent Station NJ, US
Yang Nan - Malden MA, US
Tong Wang - Cambridge MA, US
Jagdish A. Desai - Monroe Township NJ, US
James J-S Wang - Westfield NJ, US
Youhao Dong - Cambridge MA, US
Vincent S. Madison - Mountain Lakes NJ, US
Li Xiao - Cranbury NJ, US
Alan W. Hruza - Hackettstown NJ, US
M. Arshad Siddiqui - Newton MA, US
Ahmed A. Samatar - West Windsor NJ, US
Sunil Paliwal - Monroe Township NJ, US
Azim Alan Celebi - Clark NJ, US
Yiji Wu - Scotch Plains NJ, US
Sobhana Babu Boga - Scotch Plains NJ, US
Abdul-Basit Alhassan - Scotch Plains NJ, US
Xiaolei Gao - Scotch Plains NJ, US
Liang Zhu - Somerville MA, US
Mehul Patel - Waltham MA, US
Assignee:

Merck Sharp & Dohme - Rahway NJ
International Classification:

A01N 43/54
C07D 239/42
C07D 401/04
US Classification:

514256, 514247, 514277, 514396, 544315, 546 1, 546184, 5463611, 5483561, 5483601
Abstract:

Disclosed are the ERK inhibitors of formula 1. 0:.

Method Of Suppressing Prb Deficiency-Induced Tumor Formation
view source
US Patent:

20110178156, Jul 21, 2011
Filed:

Jan 19, 2011
Appl. No.:

12/930861
Inventors:

Liang Zhu - Ardsley NY, US
International Classification:

A61K 31/713
A61P 35/00
C12Q 1/48
G01N 33/53
US Classification:

514 44 A, 435 15, 435 71
Abstract:

The present invention provides methods of determining a putative agent that inhibits tumorigenesis in retinoblastoma protein deficient cells, the methods comprising determining whether the putative agent decreases phosphorylation of threonine residue 187 of p27, decreases S-phase kinase-associated protein 2 interaction with p27 having a phosphorylated threonine residue 187, or an increase in apoptosis of retinoblastoma protein deficient cells. The present invention also provides the agent, the pharmaceutical composition, and methods of inhibiting, preventing and treating tumorigenesis in retinoblastoma deficient cells, the method comprising administration of the agent that decreases phosphorylation of threonine residue 187 of p27 or the S-phase kinase-associated protein 2 interaction with p27 having a phosphorylated threonine residue 187.

Novel Compounds That Are Erk Inhibitors
view source
US Patent:

20110189192, Aug 4, 2011
Filed:

Feb 19, 2009
Appl. No.:

12/918099
Inventors:

Alan B. Cooper - Kenilworth NJ, US
Yang Nan - Cambridge MA, US
Yongqi Deng - Cambridge MA, US
Neng-Yang Shih - Cambridge MA, US
Hugh Y. Zhu - Kenilworth NJ, US
Joseph M. Kelly - Kenilworth NJ, US
Subrahmanyam Gudipati - Kenilworth NJ, US
Ronald J. Doll - Kenilworth NJ, US
Mehul F. Patel - Cambridge MA, US
Jagdish A. Desai - Kenilworth NJ, US
James J-S Wang - Kenilworth NJ, US
Sunil Paliwal - Kenilworth NJ, US
Sobhana Babu Boga - Kenilworth NJ, US
Abdul-Basit Alhassan - Kenilworth NJ, US
Xiaolei Gao - Kenilworth NJ, US
Liang Zhu - Cambridge MA, US
Xin Yao - Kenilworth NJ, US
International Classification:

A61K 31/444
C07D 401/14
C07D 409/14
C07D 417/14
A61K 31/501
A61K 39/395
A61K 31/7052
A61P 35/02
A61P 35/00
US Classification:

4241581, 546256, 544238, 514333, 51425203, 514 43, 4241721
Abstract:

Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, and solvates thereof. Q is a tetrahydropyridinyl ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Nlrc5 As A Target For Immune Therapy
view source
US Patent:

20110229560, Sep 22, 2011
Filed:

Oct 6, 2009
Appl. No.:

13/122838
Inventors:

Rong-Fu Wang - Houston TX, US
Helen Y. Wang - Houston TX, US
Jun Cui - Houston TX, US
Liang Zhu - Houston TX, US
International Classification:

A61K 9/127
A61K 31/7105
A61K 38/02
A61K 31/7088
A61K 35/12
A61P 35/00
A61P 37/04
A61P 31/00
A61P 31/04
A61P 31/12
A61P 31/06
A61P 31/18
A61P 31/16
A61P 31/10
A61P 31/14
A61P 31/22
US Classification:

424450, 514 44 A, 514 193, 514 44 R, 424 9371, 514 11
Abstract:

The present invention concerns the enhancement of immune response to microbial infection and/or inflammation-associated disease through at least partial inhibition of NLRC5. The inhibition may be of any suitable means, although in particular cases it is via siRNA agents. In specific embodiments, a particular domain of NLRC5 is targeted by the siRNA.

Novel Compounds That Are Erk Inhibitors
view source
US Patent:

20130237518, Sep 12, 2013
Filed:

Oct 24, 2011
Appl. No.:

13/881050
Inventors:

Sobhana Babu Boga - Scotch Plains NJ, US
Joseph M. Kelly - Parlin NJ, US
Hugh Y. Zhu - Warren NJ, US
Abdul-Basit Alhassan - Scotch Plains NJ, US
Xin Yao - Westfield NJ, US
Xiaolei Gao - Bridgewater NJ, US
James J-S Wang - Westfield NJ, US
Jagdish A. Desai - Monroe Township NJ, US
Subrahmanyam Gudipati - Edison NJ, US
Liang Zhu - Waltham MA, US
Alan B. Cooper - West Caldwell NJ, US
Yongqi Deng - Newton MA, US
International Classification:

C07D 401/14
C07D 471/04
C07D 417/14
C07D 409/14
A61K 31/5377
A61K 45/06
A61K 31/4545
A61K 31/444
A61K 31/454
C07D 413/14
C07D 405/14
US Classification:

51421018, 546194, 546187, 5462691, 546199, 546121, 546119, 544333, 544124, 514318, 514316, 514338, 514322, 514300, 514303, 514256, 514274, 544316, 5142345
Abstract:

Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof, wherein: A is a five membered monocyclic heteroaryl ring; and B is a monocyclic heterocycloalkyl ring, or a monocyclic heterocycloalkenyl ring, or a bridged monocyclic heterocycloalkyl ring, or a fused (monocyclic heterocycloalkyl ring) cyclopropyl ring. Also disclosed are methods of treating cancer using the compounds of formula (1).

Aminopyrimidinones As Interleukin Receptor-Associated Kinase Inhibitors
view source
US Patent:

20140329799, Nov 6, 2014
Filed:

Oct 26, 2012
Appl. No.:

14/355353
Inventors:

W. Michael Seganish - Scotch Plains NJ, US
Stephanie Nicole Brumfield - Cranbury NJ, US
Jongwon Lim - Lexington MA, US
Julius J. Matasi - Monmouth Junction NJ, US
William T. Mcelroy - Plainfield NJ, US
Deen B. Tulshian - Lebanon NJ, US
Brian J. Lavey - New Providence NJ, US
Michael D. Altman - Needham MA, US
Criag R. Gibeau - Natick MA, US
John William Lampe - Norfolk MA, US
Joey Methot - Westwood MA, US
Liang Zhu - Belmont MA, US
International Classification:

C07D 417/04
A61K 45/06
C07D 417/14
C07D 513/04
C07D 487/10
C07D 401/04
A61K 31/5377
A61K 31/513
C07D 491/107
US Classification:

51421021, 544321, 514272, 544310, 514274, 544295, 51425219, 544230, 544123, 5142352, 544319, 514269, 544296, 5142342, 540575, 514218
Abstract:

This invention relates to aminopyrimidinone compounds of Formula (I) that are inhibitors of Interleukin receptor-associated kinases, in particular IRAK-4, and are useful in the treatment or prevention of inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease.

Name / Title

Company / Classification

Phones & Addresses

Liang Zhu
President

Reach America Esg Ltd

3592 Rosemead Blvd, Rosemead, CA 91770
11100 Vly Blvd, El Monte, CA 91731

Liang Zhu
Principal

Wok N Roll
Eating Place

1821 Church Ave, Brooklyn, NY 11226

Wikipedia

Butterfly Lovers

view source

The title is often abbreviated to Liang Zhu () and often regarded as ... The legend of Liang Shanbo and Zhu Yingtai is set in the Eastern Jin Dynasty. ...